Orismilast clinical trials
Also written LEO 32731.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses orismilast is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
LEO Pharma (9) · UNION therapeutics (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Gregor Jemec (1)
Studies
Open first, then newest update. How each study uses orismilast is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Study to Assess the Efficacy and Safety of Orismilast in PsoriasisCompletedPhase 2UNION therapeuticsNCT05190419Written as Orismilast modified release tabletsHow we know
- A Study of IBI353 (Orismilast) in Chinese Healthy AdultsCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05490316Written as IBI353 (Orismilast)How we know
- Orismilast for the Treatment of Mild to Severe Hidradenitis SuppurativaStatus unknownPhase 2Gregor JemecNCT04982432Written as OrismilastHow we know
- Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.CompletedPhase 1LEO PharmaNCT03231124Written as LEO 32731How we know
- A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy PeopleCompletedPhase 1LEO PharmaNCT03812198Written as LEO 32731 modified release tabletHow we know
- Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and MidazolamCompletedPhase 1LEO PharmaNCT03126578Written as LEO 32731How we know
- LEO 32731 for the Treatment of Moderate to Severe Psoriasis VulgarisCompletedPhase 2LEO PharmaNCT02888236Written as LEO 32731How we know
- LEO 32731 - A Phase I Study in Healthy SubjectsCompletedPhase 1LEO PharmaNCT02514694Written as LEO32731How we know
- An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)CompletedPhase 1LEO PharmaNCT02496546Written as LEO 32731 creamHow we know
- A Phase I Study With LEO 32731 and Midazolam in Healthy Male SubjectsTerminatedPhase 1LEO PharmaNCT02753218Written as LEO 32731How we know
- LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy SubjectsCompletedPhase 1LEO PharmaNCT02126371Written as LEO32731How we know
- LEO 32731 - A Study in Healthy Male SubjectsCompletedPhase 1LEO PharmaNCT01310049Written as LEO 32731How we know
Codes
What other systems call orismilast · ClinicalTrials.gg INT016950
- UNII (FDA) JH1CX8SG5VORISMILASTOne source FDA
- NCI Thesaurus C175833OrismilastOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JH1CX8SG5V | ORISMILAST | One source FDA |
| NCI Thesaurus | C175833 | Orismilast | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.